ストックスクリーナーアプリを入手
131.65
0.62%
0.81
前日終値:
$130.84
開ける：
$130
24時間の取引高:
5.52M
Relative Volume:
0.85
時価総額：
$163.40B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
19.41
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
+0.96%
1か月 パフォーマンス:
-6.17%
6か月 パフォーマンス:
+9.90%
1年 パフォーマンス:
+27.51%
1日の値動き範囲:
$129.01
$132.36
1週間の範囲:
$127.64
$132.36
52週間の値動き範囲:
$95.30
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
131.65 | 163.40B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story - Yahoo Finance
The Freelux Project Announces “The Butch Queen’s Brunch & Conversations Tour” Powered by Gilead Sciences - GLAAD
Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System - MarketBeat
Oppenheimer & Co. Inc. Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Jennison Associates LLC Buys 741,044 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
US Bancorp DE Has $105.44 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences - The AI Journal
Danske Bank A S Sells 45,529 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Fifth Third Bancorp Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
GC Wealth Management RIA LLC Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Cash Flow – TSX:GILD - TradingView
Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Revenue Breakdown – TSX:GILD - TradingView
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted - MarketBeat
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir - European AIDS Treatment Group
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart.com
Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc. - MarketBeat
Gilead Sciences, Inc. $GILD Position Trimmed by State of New Jersey Common Pension Fund D - MarketBeat
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat
Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan
Is It Time To Revisit Gilead Sciences (GILD) After Recent Share Price Pullback - Yahoo Finance
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock - MarketBeat
Vanguard reports 93.3M-share, 7.51% stake in Gilead Sciences (NASDAQ: GILD) - Stock Titan
Gilead Sciences CEO Daniel O’Day sells over $1.29m in stock - Investing.com
Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan
Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st
Gilead Sciences Stock: Three Acquisitions, Four Launches, and a 20% Discount to Wall Street’s Target - TIKR.com
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir - BioSpace
GILD: Gilead's New HIV Treatment Gains FDA Acceptance - GuruFocus
Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com - Investing.com Nigeria
Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences stock edges higher as FDA grants priority review for HIV treatment - Traders Union
FDA accepts Gilead’s HIV treatment combination for review - Investing.com
Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know - MEXC
Daniel O'Day (GILD) files Form 144 to sell 10,000 performance shares - Stock Titan
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity? - CoinCentral
Gilead Sciences, Inc. completed the acquisition of 77.2% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others. - marketscreener.com
Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. - Barron's
Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc. - GuruFocus
Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel - marketscreener.com
Gilead Completes $7.8 Billion Acquisition of Arcellx - Contract Pharma
Gilead Sciences Finalizes $7.8 Billion Acquisition of Arcellx - marketscreener.com
Recent Arcellx deal leaves Gilead Sciences stock consolidating amid persistent oversold signals - Traders Union
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel - citybiz
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
1.39%
3.93%
大文字化:
|
ボリューム (24 時間):